Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HA-1 TCR-transduced virus-specific allogeneic T cells
- Development stage
- Unknown
- Lead developer
- Leiden University Medical Center
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HA-1 TCR-transduced virus-specific allogeneic T cells is an investigational adoptive cell therapy developed by the Leiden University Medical Center (LUMC). The therapy utilizes donor-derived T cells specific for Epstein-Barr virus (EBV) and/or Cytomegalovirus (CMV) that are retrovirally transduced with a T-cell receptor (TCR) specific for the minor histocompatibility antigen HA-1 (HA-1H). HA-1H is a hematopoiesis-restricted antigen presented by HLA-A*02:01, making it a selective target for inducing a graft-versus-leukemia (GVL) effect while minimizing the risk of graft-versus-host disease (GVHD). By using virus-specific T cells (VSTs) as the cellular vehicle, the therapy aims to leverage the natural persistence and safety profile of these cells in the post-transplant setting. It is primarily being evaluated for patients with high-risk leukemia or other hematologic malignancies following T-cell-depleted allogeneic stem cell transplantation.
- Other names
- HA-1 TCR-transduced virus-specific T cellsHA1 TCR-transduced virus-specific T cellsHA 1 TCR-transduced virus-specific T cellsHA-1 TCR-transduced donor T cellsHA1 TCR-transduced donor T cellsHA 1 TCR-transduced donor T cellsHA-1 TCR VSTsHA1 TCR VSTsHA 1 TCR VSTs
02
Targets
HA-1 (Minor histocompatibility antigen HA-1)Viral antigen-HLA class I peptide-MHC complex
Beyond the preview
Go deeper on HA-1 TCR-transduced virus-specific allogeneic T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HA-1 TCR-transduced virus-specific allogeneic T cells.